Patents by Inventor Sandra Zurawski

Sandra Zurawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10940195
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 9, 2021
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski
  • Publication number: 20210024641
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: June 15, 2020
    Publication date: January 28, 2021
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20200316191
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Yves LEVY, Gerard ZURAWSKI, Sandra ZURAWSKI, Anne-Laure FLAMAR
  • Patent number: 10722572
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: July 28, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, BAYLOR RESEARCH INSTITUTE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 10683361
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Patent number: 10610585
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 7, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de Paris
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Publication number: 20200101152
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: December 10, 2019
    Publication date: April 2, 2020
    Inventors: Yves LEVY, Gerard ZURAWSKI, Sandra ZURAWSKI, Anne-Laure FLAMAR
  • Patent number: 10570208
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 25, 2020
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Publication number: 20190314481
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Application
    Filed: April 29, 2019
    Publication date: October 17, 2019
    Inventors: SangKon OH, Sandra ZURAWSKI, Gerard ZURAWSKI
  • Publication number: 20190184008
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Application
    Filed: September 25, 2018
    Publication date: June 20, 2019
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 10286058
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 14, 2019
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski
  • Publication number: 20190092869
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: March 28, 2019
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Publication number: 20190085088
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: September 27, 2018
    Publication date: March 21, 2019
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Patent number: 10167339
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Patent number: 10087256
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20180000916
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon OH
  • Publication number: 20170349661
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell- (Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Application
    Filed: August 3, 2015
    Publication date: December 7, 2017
    Inventors: Yong-Jun LIU, Sandra ZURAWSKI, SangKon OH, Shino HANABUCHI, Haruyuki FUJITA, Hideki UENO, Patrick BLANCO, Hyemee JOO
  • Publication number: 20170114142
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: January 9, 2017
    Publication date: April 27, 2017
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20170106051
    Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 20, 2017
    Inventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
  • Patent number: 9567401
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 14, 2017
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh